Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flebonorm H
- Development stage
- Unknown
- Lead developer
- Amnol
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Flebonorm H is a multi-ingredient nutraceutical product developed by Amnol, specifically formulated for the management of venous and lymphatic disorders within the field of phlebology. It is composed of a synergistic blend of bioflavonoids, including diosmin, troxerutin, and hesperidin, along with a standardized extract of *Melilotus officinalis* (sweet clover). The product is primarily indicated for alleviating symptoms associated with chronic venous insufficiency (CVI) and hemorrhoidal disease. Its mechanism of action involves increasing venous tone by prolonging the activity of norepinephrine on the vascular wall, reducing capillary hyperpermeability and inflammation, and promoting lymphatic drainage through the action of coumarins found in Melilotus. As a dietary supplement, it is used to support microcirculation and overall vascular health.
- Brand names
- Flebonorm H
- Other names
- Flebonorm H-Amnol-Phlebology
02
Targets
HYAL (Hyaluronidase family (HYAL))COMT (Catechol-O-methyltransferase)
Beyond the preview
Go deeper on Flebonorm H.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flebonorm H.